ATAD2 knockdown or treatment with BAY-850 decreased glucose uptake, ATP content, and lactate level in ccRCC cells (Fig. 6A–L), while ATAD2 overexpression increased glucose uptake, ATP content, and lactate level in ccRCC cells (Fig. 6M–R). This evidence concerns the gene ATAD2 and nonpapillary renal cell carcinoma.